Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization

Journal of the American College of Cardiology

Volumn 43, Issue 12, 2004, Pages 2319-2325

  Furman, Mark I ^a   Krueger, Lori A ^a   Linden, Matthew D ^a   Barnard, Marc R ^a   Frelinger III, Andrew L ^a   Michelson, Alan D ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

EDTA; ELISA; enzyme linked immunosorbent assay; ethylenediaminetetraacetic acid; FITC; fluorescein isothiocyanate; glycoprotein; GP; HEPES Tyrode's buffer; HT; matrix metalloproteinases; MMPs; PCI; PE; PerCP; percutaneous coronary intervention; phycoerythrin

Indexed keywords

ABCIXIMAB; ACTIN; CD40 LIGAND; CYTOCHALASIN D; EDETIC ACID; EPTIFIBATIDE; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; ILOMASTAT; TIROFIBAN; TUMOR NECROSIS FACTOR;

ARTICLE; CELL SECRETION; CELL SURFACE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN POLYMERIZATION; PROTEIN SECRETION; REGULATORY MECHANISM; THROMBOCYTE; THROMBOCYTE ACTIVATION;

ACTIN DEPOLYMERIZING FACTORS; BLOOD PLATELETS; CD40 LIGAND; CHELATING AGENTS; CYTOCHALASIN D; DESTRIN; DIPEPTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; EDETIC ACID; HUMANS; MATRIX METALLOPROTEINASES; MICROFILAMENT PROTEINS; NUCLEIC ACID SYNTHESIS INHIBITORS; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROTEASE INHIBITORS; SOLUBILITY; THROMBASTHENIA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 2942546273     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2003.12.055     Document Type: Article

References (39)

1. Klinger M.H.F. Inflammation. Michelson A.D. Platelets. 2002;459-467 Academic Press/Elsevier Science, New York, NY
2. Lutgens E., Daemen M.J. CD40-CD40L interactions in atherosclerosis. Trends Cardiovasc Med. 12:2002;27-32
3. Henn V., Slupsky J.R., Grafe M., et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 391:1998;591-594
4. Aukrust P., Muller F., Ueland T., et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina Possible reflection of t lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation. 100:1999;614-620
5. Henn V., Steinbach S., Buchner K., Presek P., Kroczek R.A. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood. 98:2001;1047-1054
6. Jin Y., Nonoyama S., Morio T., Imai K., Ochs H.D., Mizutani S. Characterization of soluble CD40 ligand released from human activated platelets. J Med Dent Sci. 48:2001;23-27
7. Andre P., Nannizzi-Alaimo L., Prasad S.K., Phillips D.R. Platelet-derived CD40L The switch-hitting player of cardiovascular disease. Circulation. 106:2002;896-899
8. Andre P., Prasad K.S., Denis C.V., et al. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nature Med. 8:2002;247-252
9. Urbich C., Dernbach E., Aicher A., Zeiher A.M., Dimmeler S. CD40 ligand inhibits endothelial cell migration by increasing production of endothelial reactive oxygen species. Circulation. 106:2002;981-986
10. Mitchell W.B., Li J., Singh F., et al. Two novel mutations in the αIIb calcium-binding domains identify hydrophobic regions essential for αIIbβ3 biogenesis. Blood. 101:2003;2268-2276
11. Solorzano C.C., Ksontini R., Pruitt J.H., et al. A matrix metalloproteinase inhibitor prevents processing of tumor necrosis factor alpha (TNF alpha) and abrogates endotoxin-induced lethality. Shock. 7:1997;427-431
12. Fox J.E.B., Phillips D.R. Inhibition of actin polymerization in blood platelets by cytochalasins. Nature. 292:1981;650-652
13. Shattil S.J., Hoxie J.A., Cunningham M., Brass L.F. Changes in the platelet membrane glycoprotein IIb/IIIa complex during platelet activation. J Biol Chem. 260:1985;11107-11114
14. Amour A., Knight C.G., Webster A., et al. The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3. FEBS Letts. 473:2000;275-279
15. Kiener P.A., Moran-Davis P., Rankin B.M., Wahl A.F., Aruffo A., Hollenbaugh D. Stimulation of CD40 with purified soluble gp39 induces proinflammatory responses in human monocytes. J Immunol. 155:1995;4917-4925
16. Hollenbaugh D., Mischel-Petty N., Edwards C.P., et al. Expression of functional CD40 by vascular endothelial cells. J Exp Med. 182:1995;33-40
17. Karmann K., Hughes C.C., Schechner J., Fanslow W.C., Pober J.S. CD40 on human endothelial cells Inducibility by cytokines and functional regulation of adhesion molecule expression. Proc Natl Acad Sci USA. 92:1995;4342-4346
18. Wiley J.A., Geha R., Harmsen A.G. Exogenous CD40 ligand induces a pulmonary inflammation response. J Immunol. 158:1997;2932-2938
19. Nannizzi-Alaimo L., Rubenstein M.H., Alves V.L., Leong G.Y., Phillips D.R., Gold H.K. Cardiopulmonary bypass induces release of soluble CD40 ligand. Circulation. 105:2002;2849-2854
20. Tsakiris D.A., Tschopl M., Wolf F., Labs K.H., Jager K.A., Marbet G.A. Platelets and cytokines in concert with endothelial activation in patients with peripheral arterial occlusive disease. Blood Coagul Fibrinol. 11:2000;165-173
21. Viallard J.F., Solanilla A., Gauthier B., et al. Increased soluble and platelet-associated CD40 ligand in essential thrombocythemia and reactive thrombocytosis. Blood. 99:2002;2612-2614
22. Kato K., Santana-Sahagun E., Rassenti L.Z., et al. The soluble CD40 ligand sCD154 in systemic lupus erythematosus. J Clin Invest. 104:1999;947-955
23. Schonbeck U., Varo N., Libby P., Buring J., Ridker P.M. Soluble CD40L and cardiovascular risk in women. Circulation. 104:2001;2266-2268
24. Cairns J.A., Theroux P., Lewis H.D. Jr, Ezekowitz M., Meade T.W. Antithrombotic agents in coronary artery disease. Chest. 119:2001;228S-252S
25. Popma J.J., Ohman E.M., Weitz J., Lincoff A.M., Harrington R.A., Berger P. Antithrombotic therapy in patients undergoing percutaneous coronary intervention. Chest. 119:2001;321S-336S
26. Heeschen C., Dimmeler S., Hamm C.W., et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med. 348:2003;1104-1111
27. Nannizzi-Alaimo L., Alves V.L., Phillips D.R. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation. 107:2003;1123-1128
28. GUSTO IV-ACS Investigators, Simoons M.L. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation The gusto iv-acs randomised trial. Lancet. 357:2001;1915-1924
29. Agah R., Plow E.F., Topol E.J. GP IIb/IIIa antagonists. Michelson A.D. Platelets. 2002;769-785 Academic Press/Elsevier Science, New York, NY
30. Michelson A.D., Krueger L.A., Barnard M.R., Fox M.L., Frelinger A.L., Furman M.I. GP IIb/IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention. J Thromb Haemost. 1:2003;P1767. abstr
31. Zondlo S.C., Wang X., Feuerstein G.Z. Effects of orally active glycoprotein IIb/IIIa antagonists on platelet CD40 ligand (CD154) expression and platelet-heteroaggregate formation. Thromb Res. 106:2002;35-40
32. Chew D.P., Bhatt D.L., Sapp S., Topol E.J. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists A meta-analysis of phase iii multicenter randomized trials. Circulation. 103:2001;201-206
33. Hermann A., Rauch B.H., Braun M., Schror K., Weber A.A. Platelet CD40 ligand (CD40L) - subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets. 12:2001;74-82
34. Graf D., Muller S., Korthauer U., van Kooten C., Weise C., Kroczek R.A. A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation. Eur J Immunol. 25:1995;1749-1754
35. Weber A.A., Hermann A., Rauch B.H., Schror K. Molecular identity of platelet CD40 ligand (CD40L). Thromb Haemost. 86:2001;718. abstr
36. Michelson A.D., Ellis P.A., Barnard M.R., Matic G.B., Viles A.F., Kestin A.S. Downregulation of the platelet surface glycoprotein Ib-IX complex in whole blood stimulated by thrombin, ADP or an in vivo wound. Blood. 77:1991;770-779
37. Hato T., Ginsberg M.H., Shattil S.J. Integrin alphaIIb-beta3. Michelson A.D. Platelets. 2002;105-116 Academic Press/Elsevier Science, New York, NY
38. Adair B.D., Yeager M. Three-dimensional model of the human platelet integrin αIIbβ3 based on electron microscopy and x-ray crystallography. Proc Natl Acad Sci USA. 99:2002;14059-14064
39. Takagi J., Petre B.M., Walz T., Springer T.A. Global conformational rearrangements in integrin extracellular domains in outside-in and inside-out signaling. Cell. 110:2002;599-611